A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
NCT01955564
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
NW-3509a
Sponsor
Newron Pharmaceuticals SPA